Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-0752 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Part I - Arm 1 | EXPERIMENTAL | - |
| Part II - Arm 1 | EXPERIMENTAL | - |
| Part III - Arm 1 | EXPERIMENTAL | - |
| Part IV - Arm 1 | EXPERIMENTAL | - |
| Part V - Arm 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Comparator: MK0752, Notch Inhibitor | DRUG | Dose escalating beginning with rising dose levels of 300, 450, and 600 mg/day in a continuous dosing schedule. |
| Comparator: MK0752, Notch Inhibitor - 450 mg | DRUG | Dose 450 mg capsules daily for 28 day cycles. |
| Comparator: MK0752, Notch Inhibitor - 3 days on, 4 off | DRUG | Dose escalating in a repeating intermittent dosing schedule of 3 days on and 4 days off at rising dose levels of 450, 600, 800, 1000, 1200, and 1400 mg/day. |
| Comparator: MK0752, Notch Inhibitor - 1 day on, 6 off | DRUG | Dose escalating in a repeating intermittent dosing schedule of 1 day on/6 days off at rising dose levels of 600, 900, 1200, 1500, 1800, 2400, 3200 mg/day once weekly and then increase at 33% increments. |
| Comparator: MK0752, Notch Inhibitor - 3 days on, 4 off 350 mg | DRUG | Dose 350 mg capsules daily intermittent 3 days on/4 days off dosing. THIS DOSING SCHEDULE IS NO LONGER UNDER INVESTIGATION |
Inclusion Criteria: * Women or men greater than or equal to 18 years of age * ECOG status less than or equal to 2 (a measurement to determine your ability to perform daily activities) * In Parts I, III, and IV, patient must have a histologically confirmed, metastatic or locally advanced solid tumor...
Top 20 of 87 competitors
MK-0752 is an investigational small molecule being studied for the treatment of advanced breast cancer and other solid tumors. It was evaluated in a Phase 1 clinical trial that enrolled 103 patients. It is not approved for any indication and remains in clinical development.
MK-0752 is developed by Merck & Company, Inc., which trades on the New York Stock Exchange under the ticker symbol MRK. Merck sponsored the Phase 1 study of the drug in advanced breast cancer and other solid tumors.
MK-0752 is in Phase 1 clinical development. The single trial conducted for this drug, NCT00106145, has been completed. No active trials are currently listed. The drug has not received FDA approval and is considered investigational.
MK-0752 was studied in one completed Phase 1 trial, NCT00106145, titled "A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014)." The trial enrolled 103 patients with advanced breast cancer or other solid tumors and has finished.
Yes, MK-0752 is also known as MK0752, Comparator: MK0752, and Notch Inhibitor. These names refer to the same investigational drug developed by Merck for advanced breast cancer and other solid tumors.